Biodesix Inc (BDSX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodesix Inc (BDSX) has a cash flow conversion efficiency ratio of -1.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.17 Million) by net assets ($9.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biodesix Inc (BDSX) balance sheet quality index to measure how much of total assets are equity-financed.
Biodesix Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Biodesix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BDSX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Biodesix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodesix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
1.103x |
|
Sierra Madre Gold and Silver Ltd
V:SM
|
0.063x |
|
Selan Exploration Technology Limited
NSE:SELAN
|
0.214x |
|
Roda Vivatex Tbk
JK:RDTX
|
0.003x |
|
Alfen Beheer BV
AS:ALFEN
|
0.070x |
|
Grupo Industrial Saltillo S.A.B. de C.V
MX:GISSAA
|
0.008x |
|
Sweeten Real Estate Development Co Ltd
TW:5525
|
-0.067x |
|
ZHOU HEI YA HLDG -000001
F:ZHY
|
N/A |
Annual Cash Flow Conversion Efficiency for Biodesix Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Biodesix Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see BDSX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-2.46 Million | $-23.27 Million | 9.441x | +505.11% |
| 2024-12-31 | $20.88 Million | $-48.65 Million | -2.330x | +53.33% |
| 2023-12-31 | $4.58 Million | $-22.87 Million | -4.993x | -128.80% |
| 2022-12-31 | $20.61 Million | $-44.97 Million | -2.182x | -52.55% |
| 2021-12-31 | $19.73 Million | $-28.22 Million | -1.431x | -175.65% |
| 2020-12-31 | $41.17 Million | $-21.37 Million | -0.519x | -645.97% |
| 2019-12-31 | $-228.54 Million | $-21.73 Million | 0.095x | +6.50% |
| 2018-12-31 | $-198.03 Million | $-17.68 Million | 0.089x | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more